U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H17N3O4S
Molecular Weight 395.432
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BALAGLITAZONE

SMILES

CN1C(=O)C2=C(C=CC=C2)N=C1COC3=CC=C(CC4SC(=O)NC4=O)C=C3

InChI

InChIKey=IETKPTYAGKZLKY-UHFFFAOYSA-N
InChI=1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,16H,10-11H2,1H3,(H,22,24,26)

HIDE SMILES / InChI
Molecular Formula C20H17N3O4S
Molecular Weight 395.432
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Balaglitazone is a second generation peroxisome proliferator-activated receptor (PPAR) gamma agonist with only partial agonistic properties. It passed phase III clinical trial for the treatment of type 2 diabetes. However, Dr. Reddy's Laboratories decided to terminate further clinical development of balaglitazone.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Partial Agonist
290
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
656
BALAGLITAZONE

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
unhealthy, ADULT
n = 97
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 97
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
Disc. AE: sinusitis, oedemas...
AEs leading to
discontinuation/dose reduction:
sinusitis (2 patients)
oedemas (1 pt)
Deep vein thrombosis (2 patients)
Fatigue (2 patients)
weight increases (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
20 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
unhealthy, ADULT
n = 97
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 97
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
Disc. AE: fatigue, Deep vein thrombosis...
AEs leading to
discontinuation/dose reduction:
fatigue (3 patients)
Deep vein thrombosis (3 patients)
weight increases (3 patients)
oedemas (2 patients)
sinusitis (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
AEs

AEs

AESignificanceDosePopulation
oedemas 1 pt
Disc. AE
10 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
unhealthy, ADULT
n = 97
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 97
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
Deep vein thrombosis 2 patients
Disc. AE
10 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
unhealthy, ADULT
n = 97
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 97
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
Fatigue 2 patients
Disc. AE
10 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
unhealthy, ADULT
n = 97
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 97
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
sinusitis 2 patients
Disc. AE
10 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
unhealthy, ADULT
n = 97
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 97
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
weight increases 2 patients
Disc. AE
10 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
unhealthy, ADULT
n = 97
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 97
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
oedemas 2 patients
Disc. AE
20 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
unhealthy, ADULT
n = 97
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 97
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
Deep vein thrombosis 3 patients
Disc. AE
20 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
unhealthy, ADULT
n = 97
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 97
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
fatigue 3 patients
Disc. AE
20 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
unhealthy, ADULT
n = 97
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 97
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
sinusitis 3 patients
Disc. AE
20 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
unhealthy, ADULT
n = 97
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 97
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
weight increases 3 patients
Disc. AE
20 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
unhealthy, ADULT
n = 97
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 97
Sources:
https://pubmed.ncbi.nlm.nih.gov/21328517
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1650
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY537317
https://www.001chemical.com/chem/199113-98-9
AA Blocks
AA002BTS
https://www.aablocks.com/goods/Goods/detail?id=AA002BTS
Aaron Chemicals
AR002CLK
http://www.aaronchem.com/199113-98-9
AbMole Bioscience
M9496
http://www.abmole.com/products/balaglitazone.html
Achemtek
0102-014237
http://www.achemtek.com/199113-98-9
Ambeed
A117326
https://www.ambeed.com/products/199113-98-9.html
Ambinter
Amb24106532
http://www.ambinter.com/reference/24106532
Angel Pharmatech
AG-10098
http://www.angelpharmatech.com/199113-98-9.html
Aurum Pharmatech LLC
W-5414
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5414
BLD Pharm
BD630513
http://www.bldpharm.com/products/199113-98-9.html
BOC Sciences
199113-98-9
https://www.bocsci.com/balaglitazone-cas-199113-98-9-item-84-173178.html
BioChemPartner
BCP11371
http://www.biochempartner.com/199113-98-9-BCP11371
BioCrick
BCC1395
http://www.biocrick.com/Balaglitazone-BCC1395.html
CSNpharm
CSN18081
https://www.csnpharm.com/products/balaglitazone.html
Chem Scene
CS-1441
http://www.chemscene.com/199113-98-9.html
ChemShuttle
139018
http://www.chemshuttle.com/catalogsearch/result/?q=199113-98-9&cat=
Chemspace
CSSB00020648622
https://chem-space.com/CSSB00020648622
DC Chemicals
DC9602
http://www.dcchemicals.com/product_show-Balaglitazone.html
Debye Scientific
DB-065992
http://www.debyesci.com/cas_199113-98-9.html
Excenen
EX-A3756
https://www.excenen.com/searchresultlist.php?id=EX-A3756
Finetech
FT-0766930
http://www.finetechnology-ind.com/prod/detail/pub/199113-98-9.html
Lab Network
LN01341912
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01341912
MedChem Express
HY-16086
https://www.medchemexpress.com/balaglitazone.html
MolPort
MolPort-044-559-842
https://www.molport.com/shop/molecule-link/MolPort-044-559-842
Molcore
MC537317
https://www.molcore.com/product/199113-98-9
MuseChem
I002528
https://www.musechem.com/product/I002528.html
Smolecule
S520403
http://www.smolecule.com/products/s520403
Synblock Inc
SB16864
http://www.synblock.com/product/199113-98-9.html
THE BioTek
bt-260892
https://www.thebiotek.com/product/inhibitors/bt-260892
eNovation Chemicals
D393853
https://www.enovationchem.com/ProductDetails.asp?ProductID=D393853
eNovation Chemicals
D674931
https://www.enovationchem.com/ProductDetails.asp?ProductID=D674931
eNovation Chemicals
D763757
https://www.enovationchem.com/ProductDetails.asp?ProductID=D763757
eNovation Chemicals
D953037
https://www.enovationchem.com/ProductDetails.asp?ProductID=D953037
PubMed

PubMed

TitleDatePubMed
Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.
2012 Aug
Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist.
2012 Feb
Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy.
2016 Dec 1
Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes.
2017 Jan
Patents

Patents

06469167
1
08377950
1
JP2005162735A
1
JP2005523300A
2
JP2011144179A
1
US20090312350
1
US5885997
1
WO2006002255
1

Sample Use Guides

In Vivo Use Guide
One arm balaglitazone 10 mg, one arm balaglitazone 20 mg, orally taken once daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:29:01 GMT 2023
Edited
by admin
on Fri Dec 15 15:29:01 GMT 2023
Record UNII
4M1609828O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BALAGLITAZONE
INN   WHO-DD  
INN  
Official Name English
5-((4-((3-METHYL-4-OXO-3,4-DIHYDRO-2-QUINAZOLINYL)METHOXY)PHENYL)METHYL)THIAZOLIDINE-2,4-DIONE
Systematic Name English
(±)-5-(P-((3,4-DIHYDRO-3-METHYL-4-OXO-2-QUINAZOLINYL)METHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-((3,4-DIHYDRO-3-METHYL-4-OXO-2-QUINAZOLINYL)METHOXY)PHENYL)METHYL)-
Systematic Name English
Balaglitazone [WHO-DD]
Common Name English
NN-2344
Code English
DRF-2593
Code English
balaglitazone [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C98241
Created by admin on Fri Dec 15 15:29:01 GMT 2023 , Edited by admin on Fri Dec 15 15:29:01 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL2103991
Created by admin on Fri Dec 15 15:29:01 GMT 2023 , Edited by admin on Fri Dec 15 15:29:01 GMT 2023
PRIMARY
EVMPD
SUB25428
Created by admin on Fri Dec 15 15:29:01 GMT 2023 , Edited by admin on Fri Dec 15 15:29:01 GMT 2023
PRIMARY
CAS
199113-98-9
Created by admin on Fri Dec 15 15:29:01 GMT 2023 , Edited by admin on Fri Dec 15 15:29:01 GMT 2023
PRIMARY
NCI_THESAURUS
C78125
Created by admin on Fri Dec 15 15:29:01 GMT 2023 , Edited by admin on Fri Dec 15 15:29:01 GMT 2023
PRIMARY
FDA UNII
4M1609828O
Created by admin on Fri Dec 15 15:29:01 GMT 2023 , Edited by admin on Fri Dec 15 15:29:01 GMT 2023
PRIMARY
EPA CompTox
DTXSID30870213
Created by admin on Fri Dec 15 15:29:01 GMT 2023 , Edited by admin on Fri Dec 15 15:29:01 GMT 2023
PRIMARY
PUBCHEM
9889200
Created by admin on Fri Dec 15 15:29:01 GMT 2023 , Edited by admin on Fri Dec 15 15:29:01 GMT 2023
PRIMARY
SMS_ID
100000089460
Created by admin on Fri Dec 15 15:29:01 GMT 2023 , Edited by admin on Fri Dec 15 15:29:01 GMT 2023
PRIMARY
MESH
C497232
Created by admin on Fri Dec 15 15:29:01 GMT 2023 , Edited by admin on Fri Dec 15 15:29:01 GMT 2023
PRIMARY
DRUG BANK
DB12781
Created by admin on Fri Dec 15 15:29:01 GMT 2023 , Edited by admin on Fri Dec 15 15:29:01 GMT 2023
PRIMARY
INN
7840
Created by admin on Fri Dec 15 15:29:01 GMT 2023 , Edited by admin on Fri Dec 15 15:29:01 GMT 2023
PRIMARY
Related Record Type Details
Structure of BALAGLITAZONE, (R)-
ENANTIOMER -> RACEMATE
Structure of BALAGLITAZONE, (S)-
ENANTIOMER -> RACEMATE
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA
TARGET->PARTIAL AGONIST
Related Record Type Details
Structure of BALAGLITAZONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966